Samsara BioCapital LLC Boosts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Samsara BioCapital LLC lifted its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 584,642 shares of the company's stock after purchasing an additional 59,642 shares during the quarter. Jasper Therapeutics accounts for approximately 2.1% of Samsara BioCapital LLC's holdings, making the stock its 14th largest position. Samsara BioCapital LLC owned approximately 3.87% of Jasper Therapeutics worth $10,997,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in JSPR. Braidwell LP bought a new position in Jasper Therapeutics in the 3rd quarter worth $9,091,000. Verition Fund Management LLC acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at approximately $477,000. Ally Bridge Group NY LLC boosted its holdings in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock valued at $7,514,000 after buying an additional 180,852 shares during the period. MetLife Investment Management LLC boosted its position in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock worth $129,000 after acquiring an additional 3,873 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock worth $47,000 after acquiring an additional 1,698 shares in the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on JSPR. Cantor Fitzgerald reiterated an "overweight" rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. HC Wainwright reiterated a "buy" rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. JMP Securities restated a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Royal Bank of Canada lowered their target price on Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 14th. Finally, Evercore ISI restated an "outperform" rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $74.86.

Jasper Therapeutics Stock Down 7.4 %

Shares of Jasper Therapeutics stock traded down $1.70 during trading on Thursday, reaching $21.39. The company's stock had a trading volume of 157,078 shares, compared to its average volume of 175,382. The company has a market cap of $320.85 million, a price-to-earnings ratio of -4.57 and a beta of 2.18. The firm's 50-day moving average is $20.42 and its two-hundred day moving average is $20.94. Jasper Therapeutics, Inc. has a 52-week low of $4.00 and a 52-week high of $31.01.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.